secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001140361-25-032012
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals: FDA lifts clinical hold on Phase 2 trial of RP-A501 for Danon disease
--------------------------------------------------------------------------------

- FDA lifted clinical hold in under 3 months; trial resumes with recalibrated dose 3.8x10^13 GC/kg for 3 patients with 4-week intervals.
- Revised immunomodulatory regimen: discontinue prophylactic C3 inhibitor, maintain sirolimus/rituximab/steroids, lower eculizumab threshold.
- Phase 2 trial is 12-patient single-arm; co-primary endpoint: LAMP2 expression and left ventricular mass reduction; key secondary: troponin change.
- Six patients previously treated at 6.7x10^13 GC/kg; three additional at lower dose to be treated sequentially.
- Natural history study running concurrently; all patients require 3-month pre-treatment run-in for biomarker assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125032012/0001140361-25-032012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125032012/ef20054253_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer